Registry of Lobbyists

Registration - In-house Corporation

Hoffmann-La Roche Limited / BRIGITTE NOLET, PRESIDENT AND CHIEF EXECUTIVE OFFICER

Registration Information

In-house Corporation name: Hoffmann-La Roche Limited
Previous in-house corporation names
Responsible Officer Name: BRIGITTE NOLET, PRESIDENT AND CHIEF EXECUTIVE OFFICER 
Responsible Officer Change History
Initial registration start date: 2001-01-18
Registration status: Active
Registration Number: 952745-64

Associated Communications

Total Number of Communication Reports: 435

Monthly communication reports in the last 6 months: 18

Version 1 of 63 (2001-01-18 to 2002-01-30)

Version 1 of 63 (2001-01-18 to 2002-01-30) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Information about Lobbyist and Corporation

Corporation: HOFFMANN-LA ROCHE LIMITED
2455 MEADOWPINE BLVD.
MISSISSAUGA, ON  L5N 6L7
Canada
Telephone number: 905-542-5555
Fax number: 905-542-7130  
Responsible officer name and position during the period of this registration: RONNIE MILLER, PRESIDENT AND CEO  
Description of activities: PHARMACEUTICALS, VITAMINS & FINE CHEMICALS, DIAGNOSTICS, FLAVOURS AND FEED PRE-MIXES
 
The client is a subsidiary of the following parent companies: F. HOFFMANN-LA ROCHE LIMITED
POSTFACH 4002
BASEL
Switzerland

Coalition The corporation is not a member of a coalition.
Subsidiary: The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking.
Other direct interests The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
 
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Health Canada (HC), Industry Canada
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Meetings, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Health, Intellectual Property, International Relations
 
Subject Matter: Particulars: BILLS OR RESOLUTIONS RE: REVIEW OF DRUG PATENT LEGISLATION (FORMERLY BILL C-91)




Date Modified: